Using fisetin to improve walking ability in older adults with peripheral artery disease
FIsetin to Reduce Senescence and mobility impairmenT in PAD: the FIRST Pilot Randomized Trial
This study is looking at whether a natural compound called fisetin can help older adults with peripheral artery disease move better and feel younger by reducing certain aging cells in their legs. Participants will take either fisetin or a placebo, and researchers will check how their walking and muscle strength improve over time.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10691354 on NIH RePORTER |
What this research studies
This research investigates the effects of fisetin, a natural compound, on improving mobility and reducing cellular aging in older adults suffering from peripheral artery disease (PAD). The study aims to determine if fisetin can decrease the accumulation of senescent cells in the lower extremities, which are linked to mobility impairments. Participants will be randomly assigned to receive either fisetin or a placebo, and their walking ability and muscle function will be assessed over time. The approach focuses on understanding how reducing senescent cells can enhance physical function and quality of life for those affected by PAD.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults diagnosed with peripheral artery disease who experience mobility impairments.
Not a fit: Patients without peripheral artery disease or those who are not experiencing mobility issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve mobility and quality of life for older adults with PAD.
How similar studies have performed: While the approach of using senolytic therapies like fisetin is promising, it is still relatively novel and has not been extensively tested in the context of PAD.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Mcdermott, Mary Mcgrae — Northwestern University at Chicago
- Study coordinator: Mcdermott, Mary Mcgrae
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.